41O Stock Overview
Operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Outlook Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.35 |
| 52 Week High | US$10.00 |
| 52 Week Low | US$4.44 |
| Beta | 0.63 |
| 11 Month Change | 12.40% |
| 3 Month Change | -16.41% |
| 1 Year Change | -39.75% |
| 33 Year Change | -84.94% |
| 5 Year Change | -75.90% |
| Change since IPO | -89.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 41O | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.9% | -0.4% | -1.8% |
| 1Y | -39.8% | -15.4% | 13.6% |
Return vs Industry: 41O underperformed the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: 41O underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| 41O volatility | |
|---|---|
| 41O Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 41O's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 41O's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 24 | Russ Trenary | www.outlooktherapeutics.com |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte.
Outlook Therapeutics, Inc. Fundamentals Summary
| 41O fundamental statistics | |
|---|---|
| Market cap | €131.15m |
| Earnings (TTM) | -€86.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs 41O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 41O income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$34.18m |
| Gross Profit | -US$34.18m |
| Other Expenses | US$59.86m |
| Earnings | -US$94.05m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -38.8% |
How did 41O perform over the long term?
See historical performance and comparison